Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

Yan Feng, Bruce G. Pollock, Kim Coley, Stephen Marder, Del Miller, Margaret Kirshner, Manickam Aravagiri, Lon Schneider, Robert Bies

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

AIMS: To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters. METHODS: PK analysis used plasma samples collected from the Clinical Antipsychotic Trials of Intervention Effectiveness. A nonlinear mixed-effects model was developed using nonmem to describe simultaneously the risperidone and 9-OH risperidone concentration-time profile. Covariate effects on risperidone and 9-OH risperidone PK parameters were assessed, including age, weight, sex, smoking status, race and concomitant medications. RESULTS: PK samples comprised 1236 risperidone and 1236 9-OH risperidone concentrations from 490 subjects that were available for analysis. Ages ranged from 18 to 93 years. Population PK submodels for both risperidone and 9-OH risperidone with first-order absorption were selected to describe the concentration-time profile of risperidone and 9-OH risperidone. A mixture model was incorporated with risperidone clearance (CL) separately estimated for three subpopulations [poor metabolizer (PM), extensive metabolizer (EM) and intermediate metabolizer (IM)]. Age significantly affected 9-OH risperidone clearance. Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h-1 and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively. CONCLUSIONS: A one-compartment mixture model with first-order absorption adequately described the risperidone and 9-OH risperidone concentrations. Age was identified as a significant covariate on 9-OH risperidone clearance in this study.

Original languageEnglish (US)
JournalBritish Journal of Clinical Pharmacology
Volume66
Issue number5
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Risperidone
Pharmacokinetics
Population
Paliperidone Palmitate
Antipsychotic Agents
Half-Life
Smoking
Clinical Trials
Weights and Measures

Keywords

  • CATIE trial
  • CYP2D6
  • NONMEM
  • Pharmacokinetics
  • Risperidone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. / Feng, Yan; Pollock, Bruce G.; Coley, Kim; Marder, Stephen; Miller, Del; Kirshner, Margaret; Aravagiri, Manickam; Schneider, Lon; Bies, Robert.

In: British Journal of Clinical Pharmacology, Vol. 66, No. 5, 11.2008.

Research output: Contribution to journalArticle

Feng, Yan ; Pollock, Bruce G. ; Coley, Kim ; Marder, Stephen ; Miller, Del ; Kirshner, Margaret ; Aravagiri, Manickam ; Schneider, Lon ; Bies, Robert. / Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. In: British Journal of Clinical Pharmacology. 2008 ; Vol. 66, No. 5.
@article{f305a883740f4c7e8bfb3dc8415fc7b2,
title = "Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study",
abstract = "AIMS: To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters. METHODS: PK analysis used plasma samples collected from the Clinical Antipsychotic Trials of Intervention Effectiveness. A nonlinear mixed-effects model was developed using nonmem to describe simultaneously the risperidone and 9-OH risperidone concentration-time profile. Covariate effects on risperidone and 9-OH risperidone PK parameters were assessed, including age, weight, sex, smoking status, race and concomitant medications. RESULTS: PK samples comprised 1236 risperidone and 1236 9-OH risperidone concentrations from 490 subjects that were available for analysis. Ages ranged from 18 to 93 years. Population PK submodels for both risperidone and 9-OH risperidone with first-order absorption were selected to describe the concentration-time profile of risperidone and 9-OH risperidone. A mixture model was incorporated with risperidone clearance (CL) separately estimated for three subpopulations [poor metabolizer (PM), extensive metabolizer (EM) and intermediate metabolizer (IM)]. Age significantly affected 9-OH risperidone clearance. Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h-1 and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively. CONCLUSIONS: A one-compartment mixture model with first-order absorption adequately described the risperidone and 9-OH risperidone concentrations. Age was identified as a significant covariate on 9-OH risperidone clearance in this study.",
keywords = "CATIE trial, CYP2D6, NONMEM, Pharmacokinetics, Risperidone",
author = "Yan Feng and Pollock, {Bruce G.} and Kim Coley and Stephen Marder and Del Miller and Margaret Kirshner and Manickam Aravagiri and Lon Schneider and Robert Bies",
year = "2008",
month = "11",
doi = "10.1111/j.1365-2125.2008.03276.x",
language = "English (US)",
volume = "66",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

AU - Feng, Yan

AU - Pollock, Bruce G.

AU - Coley, Kim

AU - Marder, Stephen

AU - Miller, Del

AU - Kirshner, Margaret

AU - Aravagiri, Manickam

AU - Schneider, Lon

AU - Bies, Robert

PY - 2008/11

Y1 - 2008/11

N2 - AIMS: To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters. METHODS: PK analysis used plasma samples collected from the Clinical Antipsychotic Trials of Intervention Effectiveness. A nonlinear mixed-effects model was developed using nonmem to describe simultaneously the risperidone and 9-OH risperidone concentration-time profile. Covariate effects on risperidone and 9-OH risperidone PK parameters were assessed, including age, weight, sex, smoking status, race and concomitant medications. RESULTS: PK samples comprised 1236 risperidone and 1236 9-OH risperidone concentrations from 490 subjects that were available for analysis. Ages ranged from 18 to 93 years. Population PK submodels for both risperidone and 9-OH risperidone with first-order absorption were selected to describe the concentration-time profile of risperidone and 9-OH risperidone. A mixture model was incorporated with risperidone clearance (CL) separately estimated for three subpopulations [poor metabolizer (PM), extensive metabolizer (EM) and intermediate metabolizer (IM)]. Age significantly affected 9-OH risperidone clearance. Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h-1 and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively. CONCLUSIONS: A one-compartment mixture model with first-order absorption adequately described the risperidone and 9-OH risperidone concentrations. Age was identified as a significant covariate on 9-OH risperidone clearance in this study.

AB - AIMS: To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters. METHODS: PK analysis used plasma samples collected from the Clinical Antipsychotic Trials of Intervention Effectiveness. A nonlinear mixed-effects model was developed using nonmem to describe simultaneously the risperidone and 9-OH risperidone concentration-time profile. Covariate effects on risperidone and 9-OH risperidone PK parameters were assessed, including age, weight, sex, smoking status, race and concomitant medications. RESULTS: PK samples comprised 1236 risperidone and 1236 9-OH risperidone concentrations from 490 subjects that were available for analysis. Ages ranged from 18 to 93 years. Population PK submodels for both risperidone and 9-OH risperidone with first-order absorption were selected to describe the concentration-time profile of risperidone and 9-OH risperidone. A mixture model was incorporated with risperidone clearance (CL) separately estimated for three subpopulations [poor metabolizer (PM), extensive metabolizer (EM) and intermediate metabolizer (IM)]. Age significantly affected 9-OH risperidone clearance. Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h-1 and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively. CONCLUSIONS: A one-compartment mixture model with first-order absorption adequately described the risperidone and 9-OH risperidone concentrations. Age was identified as a significant covariate on 9-OH risperidone clearance in this study.

KW - CATIE trial

KW - CYP2D6

KW - NONMEM

KW - Pharmacokinetics

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=55149091794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55149091794&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2008.03276.x

DO - 10.1111/j.1365-2125.2008.03276.x

M3 - Article

VL - 66

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 5

ER -